Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
HARMONi
Phase III Study of AK112 for NSCLC Patients
- NCT06396065 ↗
- Active, not recruiting
- Summit Therapeutics
- Deep
We haven't built an HCP commentary report on HARMONi (AK112 in Non-Squamous Non-small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on HARMONi so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 127 | |
| YouTube | 11 | |
| Podcasts | 11 | |
| X videos | 4 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-Squamous Non-small Cell Lung Cancer
- Interventions
- AK112 Injection; Placebo Injection
- Arms
- AK112 in combination with Pemetrexed and Carboplatin · Experimental
- Placebo in combination with Pemetrexed and Carboplatin · Active comparator
- Enrollment
- 420
- Primary outcomes
- Progression-free survival (PFS)
- Overall Survival (OS) in the ITT population
- Sponsor
- Summit Therapeutics with Akeso
- Start
- May 4, 2023
- Primary completion
- Apr 12, 2025
- Results posted
- No
- Registry record
- NCT06396065 · updated Jul 28, 2026
Publications
linked from the registry- Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N, Popat S, Fang W, Luo Y, Li W, He Z, Zhao H, Li M, Song Q, Zhao H, El Darsa H, Monnet I, Cobo Dols M, Garcia Campelo R, Jotte R, Berz D, Spira A, Perol M, Nagasaka M, West H, Styles L, Li J, Clow F, Goldman J, Zhang L. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2026 Sep;27(9):1094-1109. doi: 10.1016/S1470-2045(26)00282-2. PubMed 42636833